Cortés Adriana, Romero-Murillo Silvia, Anaya-Cubero Elena, Cartas-Cejudo Paz, Extramiana Leire, Lachén-Montes Mercedes, Fernández-Irigoyen Joaquín, Santamaría Enrique
Clinical Neuroproteomics Unit, Proteomics Platform, Navarrabiomed, Hospital Universitario de Navarra (HUN), Universidad Pública de Navarra (UPNA), IdiSNA, Pamplona, Spain.
Methods Mol Biol. 2025;2914:323-332. doi: 10.1007/978-1-0716-4462-1_22.
Selecting a fluid near an affected organ can improve the likelihood of identifying a biomarker panel from pathological tissue. Cerebrospinal fluid (CSF), in close contact with the brain, is a valuable source of biomarkers for neurological disorders due to the inaccessibility of brain tissue. Moreover, the altered CSF proteome identified in neurological diseases can facilitate the repurposing of drugs already used for other therapeutic purposes. In this context, Connectivity Map (CMap) is a valuable tool as it provides information on compounds and gene modifications that can be utilized to reverse specific pathological signatures. Analyzing CSF differential proteomics through the CMap framework offers an efficient and cost-effective approach to identifying potential novel therapies for neurodegenerative diseases.
在受影响器官附近选择一种体液可以提高从病理组织中识别生物标志物组的可能性。脑脊液（CSF）与大脑密切接触，由于脑组织难以获取，它是神经系统疾病生物标志物的宝贵来源。此外，在神经疾病中鉴定出的脑脊液蛋白质组改变可以促进已用于其他治疗目的药物的重新利用。在这种情况下，连通性图谱（CMap）是一种有价值的工具，因为它提供了可用于逆转特定病理特征的化合物和基因修饰信息。通过CMap框架分析脑脊液差异蛋白质组学为识别神经退行性疾病潜在的新型疗法提供了一种高效且经济有效的方法。
